{"question": "Statement 1: Manufacturers can apply for exemptions from radiation safety warnings if they demonstrate the microwave oven model continues to comply with performance standards under adverse conditions addressed by those warnings. Statement 2: The application for exemption must include data showing why specific radiation safety warnings are unnecessary, but does not require submission of product samples unless specifically requested by regulatory authorities.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Monolingual", "explanation": "Statement 1 correctly describes the exemption process where manufacturers must demonstrate continued compliance under adverse conditions. Statement 2 accurately reflects that applications require data establishing why warnings are unnecessary, and product samples are only required if specifically requested by the Director or regulations.", "category": "Medical_Devices", "related_concept": "radiation safety warning exemption", "id": "US_147_006", "match_type": "monolingual", "lang": "EN", "source": "PART_1030PERFORMANCE_STANDARDS_FOR_MICROWAVE_AND_R.txt", "old_id": "mono_0003_2"}
{"question": "In FDA regulatory proceedings for minor species drugs, what constitutes the exclusive record for decision-making during informal conferences?", "choices": ["A. The administrative record of the informal conference", "B. The sponsor's written submission only", "C. The investigator's clinical trial data", "D. The Director of OMUMS' recommendation"], "answer": "A", "type": "Monolingual", "explanation": "The administrative record of the informal conference serves as the exclusive record for decision-making in these proceedings, meaning no other documents or records outside this administrative record are considered for the final decision.", "category": "Drugs", "related_concept": "exclusive record for decision", "id": "US_084_027", "match_type": "monolingual", "lang": "EN", "source": "PART_516NEW_ANIMAL_DRUGS_FOR_MINOR_USE_AND_MINOR_S.txt", "old_id": "mono_0014_1"}
{"question": "关于血液制品生产企业的生物安全与人员健康管理，请判断以下陈述：陈述1：所有从事血液制品生产、质量保证、质量控制及相关人员必须接受生物安全防护培训，特别是预防经血液传播疾病的培训。陈述2：境内血液制品生产企业必须为所有生产、质量保证、质量控制及相关人员接种预防经血液传播疾病的疫苗。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都错误", "C. 陈述1正确，陈述2错误", "D. 陈述1错误，陈述2正确"], "answer": "A", "type": "Monolingual", "explanation": "根据《血液制品附录》第九条，从事血液制品生产、质量保证、质量控制及其他相关人员应当经过生物安全防护的培训，尤其是经过预防经血液传播疾病方面的知识培训，因此陈述1正确。第十条规定，境内从事血液制品生产、质量保证、质量控制及其他相关人员应当接种预防经血液传播疾病的疫苗，因此陈述2正确。两者均符合法规要求，故两个陈述都正确。", "category": "Drugs", "related_concept": "biosecurity training for personnel, vaccination requirements for personnel", "id": "CN_084_002", "match_type": "monolingual", "lang": "CN", "source": "血液制品附录（2020年第77号公告修订）.txt", "old_id": "mono_0002_2"}
{"question": "When reporting a successful import of controlled substances to the DEA, which specific dates must be documented to demonstrate proper chain of custody?", "choices": ["A. The date of shipment departure and the date of customs clearance", "B. The date of customs release and the date of arrival at the registered location", "C. The date of permit issuance and the date of final delivery", "D. The date of purchase order and the date of warehouse receipt"], "answer": "B", "type": "Monolingual", "explanation": "For proper chain of custody documentation, the DEA requires reporting both the date the controlled substance was released by customs at the port of entry and the date it arrived at the registered location. These dates are essential for tracking the substance's movement and ensuring regulatory compliance.", "category": "Controlled_Substances", "related_concept": "release date at port of entry, arrival date at registered location", "id": "US_013_005", "match_type": "monolingual", "lang": "EN", "source": "PART_1312IMPORTATION_AND_EXPORTATION_OF_CONTROLLED.txt", "old_id": "mono_0004_1"}
{"question": "在中药生产监管中，药品监督管理部门对持有人和中药生产企业划分风险等级时，主要考虑哪些因素？请选择所有正确选项的组合。① 中药的品种、剂型和管理类别 ② 既往检查、抽检、不良反应监测等风险情况 ③ 企业推进中药材GAP实施、生产智能化改造等情况 ④ 企业注册资本和年营业额规模", "choices": ["A. ①②③", "B. ①③④", "C. ②③④", "D. ①②④"], "answer": "A", "type": "Monolingual", "explanation": "药品监督管理部门划分风险等级时，应综合考虑中药品种、剂型、管理类别等固有属性，结合既往检查、抽检、不良反应监测、投诉举报等历史风险数据，以及企业主动推进中药材GAP实施、生产智能化改造、全链条追溯等质量管理提升情况。企业注册资本和年营业额规模并非法规规定的风险分级依据，因此④不正确。", "category": "Drugs", "related_concept": "risk-based regulatory classification", "id": "CN_032_024", "match_type": "monolingual", "lang": "CN", "source": "中药生产监督管理专门规定.txt", "old_id": "mono_0012_2"}
